HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NRT Petition Calls On FDA To Greatly Expand Indications, Availability

This article was originally published in The Tan Sheet

Executive Summary

FDA's stated commitment to a public health approach to drug regulation will be put to the test by a petition to expand nicotine replacement therapy indications and availability

You may also be interested in...

Education About NRT Safety Overcomes Smokers’ Cost Barrier – Study

Drug firms could educate consumers about the safety and efficacy of nicotine-replacement therapies to show the products’ value, according to recent research.

Smoking Cessation Growth Opportunities Lay With Employers, Health Care Reform

Many employers still hold a short-sighted view of the cost of smoking cessation therapies, panelists at an American University webinar said Nov. 16.

FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds

Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts